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ABSTRACT
Background
Despite recommendations favouring review of cancer 
pathology specimens for patients being treated at an 
institution other than the one that produced the initial 
pathology report, data regarding discordance rates and 
their potential clinical impact remain limited, particu-
larly for breast cancer. At the QEII Health Sciences 
Centre in Halifax, Nova Scotia, it was routine practice 
to review histopathology when patients referred for 
adjuvant therapy had undergone their breast cancer 
surgery and pathology reporting at another institu-
tion. The aim of the present study was to determine 
the rate and clinical impact of discordance in inter-
institutional pathology consultations for breast cancer 
in Nova Scotia.
Methods
We conducted a retrospective review of 100 randomly 
selected inter-institutional pathology consultations 
for breast cancer patients referred to the QEII in 
2004. Cases were categorized as having either no 
discordance, discordance with no clinical impact, or 
discordance with potential for clinical impact. Cases 
with potential clinical impact were independently 
reviewed by 2 medical oncologists and 2 radiation 
oncologists, and the discordances were rated as hav-
ing high, medium, or no clinical impact.
Results
The study cohort consisted of 93 cases that met the 
inclusion criteria. Of these 93 cases, 6 had no discor-
dance, 7 had discordance with no clinical impact, and 
80 had discordance with potential for clinical impact. 
Overall, 10 cases (11%) were rated as having either 
high or medium clinical impact, with agreement on 
the clinical impact ratings by oncologist reviewers in 
the same specialty. The remaining cases had either 
no clinical impact or disagreement on the clinical 
impact rating.
Conclusions
Inter-institutional pathology consultations for breast 
cancer in Nova Scotia identified discordant find-
ings with potential clinical impact as determined by 
oncologist reviewers. Further evaluation of inter-
institutional pathology consultations and the impact 
on clinical decision-making is warranted.
KEY WORDS
Breast cancer, surgical pathology, pathology review, 
quality assurance
1.  INTRODUCTION
Breast cancer is the most common noncutaneous 
cancer arising in Canadian women. New breast can-
cer cases in Canada were estimated to reach 22,600 
in 2009, with 5400 deaths from the disease. In Nova 
Scotia, new diagnoses were estimated to reach 690, 
with 190 breast cancer-related deaths 1.
Nova Scotia has two tertiary oncology referral 
centres, based in Halifax and Sydney. However, 
approximately half of new breast cancer surgeries 
in the province are performed outside the surgical 
catchment areas of those two regions 2. Pathology 
for patients who have breast cancer surgery at hos-
pitals throughout mainland Nova Scotia (excluding 
Cape Breton) is reported at the local institution, and 
most patients are then referred to the QEII Health 
Sciences Centre in Halifax for adjuvant medical and 
radiation oncology assessment.
Until 2005, it had been routine practice for the 
histopathology accompanying each patient referral 
to be systematically reviewed by one of a team of 
four QEII pathologists with interest and exper-
tise in breast pathology. This review is called an 
inter-institutional pathology consultation. These 
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consultations are a component of quality assurance 
in pathology and are distinct from direct pathologist-
to-pathologist consultations for second opinions on 
challenging cases. Although this quality assurance 
procedure was routine practice at our centre, it was 
never systematically evaluated. Specifically, the rate 
of discordance between the pathology reports and 
the clinical impact of the pathology reviews were 
unknown. In recent years, complete pathology re-
view of external cases has been reduced because of 
workload constraints.
Previous studies of inter-institutional pathology 
consultations for a cancer diagnosis have reported 
overall discordance rates ranging from 1.4% to 
9.0% 3–7. Discordance rates for breast cancer 
pathology have ranged from 1.4% to 6.3% 3–5, 
and breast cancer–specific pathology reviews 
performed as part of a dedicated multidisciplinary 
tumour board have observed a 4%–29% discor-
dance rate 8,9. In most of these series, information 
regarding the specific discordant elements and the 
potential clinical impact of the discordant findings 
is limited.
The aim of the present study was to determine 
the rate, types, and potential clinical impact of dis-
cordance in inter-institutional pathology consultations 
for breast cancer in Nova Scotia.
2.  METHODS
We conducted a retrospective review of 100 random-
ly selected inter-institutional pathology consultations 
for patients with breast cancer referred to the QEII 
Health Sciences Centre during January 1–Decem-
ber 31, 2004. The computerized anatomic pathology 
files (Cerner Classic: Cerner Corporation, Kansas 
City, MO, U.S.A.) were used to identify all breast 
cancer inter-institutional pathology consultations 
performed in 2004 and to generate a summary of the 
consultant’s findings for each case. These summaries 
were reviewed independently by two investigators 
(JAP, PJB) to determine eligibility. Figure 1 shows 
total cases and reasons for exclusion. In cases of 
uncertainty, the reports were discussed by the two 
investigators, and a consensus was reached. From 
among the eligible cases, 100 were randomly se-
lected with the use of a computer-generated random-
number sequence. The original pathologist’s reports 
and the consultant’s reports for these 100 cases were 
obtained from the QEII Department of Pathology 
and were reviewed to identify any further cases for 
exclusion. All patient identifiers were removed from 
the reports.
For eligible cases, key data elements (Table i) 
were abstracted from the original and consulta-
tion pathology reports based on the breast cancer 
synoptic reporting format currently in use in Nova 
Scotia. Data abstraction was performed by a single 
unblinded investigator (JAP). Based on pre-specified 
criteria, cases were categorized according to degree 
of discordance:
●  No discordance
●  Discordance with no clinical impact (Table ii pre-
sents the specific discordant criteria considered 
to have no clinical impact.)
●  Discordance with potential for clinical impact
For each case having discordance with potential clini-
cal impact, a summary was prepared of abstracted 
data from the original and consultation reports. The 
identity of the summarized report as either original 
or consultation was indicated. These summary tables 
were provided to 2 medical oncologists and 2 ra-
diation oncologists with breast cancer subspecialty 
interest and expertise who, blinded to the other re-
viewers, assessed the summaries and classified each 
discordant case as having either high, medium, or no 
clinical impact. “High clinical impact” was defined 
as the potential to lead to a change in the intent of 
treatment or in the treatment modality recommended. 
“Medium clinical impact” was defined as a potential 
to change the type or duration of treatment (or both) 
within a modality or to change the emphasis placed on 
a recommended modality. Radiotherapy, chemother-
apy, hormonal therapy, and additional surgery were 
considered separate modalities. For cases classified 
as having discordance with high or medium clinical 
f i g u r e  1  Identification of cases for inclusion.27
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impact, oncologist reviewers were asked to specifi-
cally describe the potential therapeutic implications 
of the discordance.
Descriptive statistics were used to depict the pro-
portion of cases with clinical impact. Kappa statistics 
were used to compare clinical impact ratings between 
oncologists within the same discipline. Approval 
for the study was obtained from the Capital Health 
Research Ethics Board.
3.  RESULTS
We identified 257 cases as potential candidates for 
inclusion. Of the potential cases, 61 were excluded for 
the reasons presented in Figure 1. Of the remaining 
196 cases, 100 were randomly selected for the study. 
After the complete reports had been reviewed, 7 more 
were subsequently excluded (Figure 1), leaving 93 
cases in the study cohort.
For the included cases, the original pathology was 
reported by 10 pathologists at 5 separate centres. In 
30 cases, the original pathology was performed by the 
same pathologist, and 39 reports came from a single 
institution. Consultations at the QEII were performed 
by 1 of the 4 pathologists with breast pathology inter-
est and expertise, with 2 of those 4 pathologists ac-
counting for 68 and 22 of the consultations. Table iii 
shows the clinicopathologic characteristics from the 
original pathology reports for the entire cohort.
After review of the original and consultation 
pathology reports, 6 of the 93 cases were assessed 
to have no discordance; 7, to have discordance with 
no clinical impact as determined by the pre-specified 
criteria (Table ii); and 80, to have discordance with 
potential for clinical impact. These latter 80 cases 
were then reviewed independently by 2 medical 
oncologists and 2 radiation oncologists with subspe-
cialty expertise in breast cancer.
Figures 2 and 3 present the results of the oncolo-
gists’ categorization of discordant cases with potential 
clinical impact. Opinions from the 2 medical oncolo-
gists regarding clinical impact agreed for 58 of the 80 
cases reviewed: both medical oncologists rated 51 
discordances as having no clinical impact, 6 as having 
high clinical impact, and 1 as having medium clinical 
impact (Figure 2). Opinions from the 2 radiation on-
cologists regarding clinical impact agreed for 67 of the 
80 cases reviewed: both radiation oncologists rated 64 
as having no clinical impact and 3 as having medium 
clinical impact (Figure 3). Overall, 10 cases (11%) 
in the study cohort met our criteria for either high or 
medium clinical impact, with agreement between the 
oncologist reviewers in each oncology specialty.
For 22 cases, the medical oncologists disagreed 
on clinical impact. In 21 cases, either high or medium 
clinical impact was assessed by one reviewer, but 
the other reviewer assessed no clinical impact; in 1 
case, high impact was assessed by one medical on-
cologist and medium impact by the other (Figure 2). 
t a b l e  i  Data elements abstracted from the original and consulta-
tion pathology reports
Type of data Elements abstracted
Referral information Referring hospital
Surgeon
Original and consulting pathologists
Patient age
Type of surgery
Dates of surgery and pathology 
reports
Number of slides and blocks 
submitted
Use of synoptic reporting format
Pathologic features of 
invasive carcinoma
Tumour size
Histologic type
Chest wall, skin, nipple involvement
Distribution (multifocal, multicentric)
Nottingham grade
Lymphovascular invasion
In situ component subtype and 
nuclear grade
Extensive intraductal component 
status
Resection margin status
Distance to nearest margin
If margin involved, specify site
If margin involved, in situ or invasive 
at margin
If margin involved, macroscopic or 
microscopic
Type of nodal surgery
Number of nodes resected and 
number involved
Size of nodal metastases
Presence of extranodal extension
Hormone receptor status
Human epidermal growth factor 
receptor (h e r 2/neu) status
Pathologic features of  
in situ carcinoma
Size
Extent (number of blocks involved)
Histologic type and subtype
Distribution (multifocal, multicentric)
Resection margin status
Distance to nearest margin
If margin involved, specify site
Type of nodal surgery (if applicable)
Number of nodes resected and 
number involved
Size of nodal metastases
Presence of extranodal extension28
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The weighted kappa statistic for agreement between 
the medical oncologists was 0.36 [95% confidence 
interval (c i ): 0.12 to 0.60].
For 13 cases, the radiation oncologists disagreed 
on clinical impact. In 12 cases, either high or medium 
clinical impact was assessed by one reviewer, but the 
other reviewer assessed no clinical impact; in 1 case, 
high impact was assessed by one radiation oncologist 
and medium impact by the other (Figure 3). The 
weighted kappa statistic for agreement between the ra-
diation oncologists was 0.20 (95% c i : –0.03 to 0.44).
Table iv details the main reasons for discordance 
in the 6 discordant cases rated as having high clinical 
PRICE et al.
t a b l e  ii  Pre-specified criteria for discordant elements to be clas-
sified as having no clinical impact
Pathologic feature Discordance with no clinical impact
Distance of tumour to 
closest margin
●  Distance different, but 2 mm or more 
in both reports
●  Distance 2 mm or more in one report 
and not described in other report
In situ component ●  Size of in situ component not  
described
●  Stated as not present in one report and 
not described in other report
Extracapsular nodal 
extension
●  Stated as not present in one report and 
not described in other report
Extensive intraductal 
component
●  Stated as negative in one report and 
not described in other report
Nipple, skin,  
chest wall
●  Omitted in description if uninvolved
Hormone receptor 
status
●  Not performed at referring hospital or 
pending at time of referral
h e r 2/neu ●  Not considered for discordance,  
because tested only at QEII Health 
Sciences Centre
f i g u r e  2  Rating of 80 cases with potential for clinical impact (medi-
cal oncologist 1 by medical oncologist 2). Weighted kappa (95% 
confidence limits): 0.36 (0.12, 0.60). (Kappa < 0.20 = poor agree-
ment; 0.20–0.40 = fair agreement; 0.40–0.60 =moderate agreement; 
0.60–0.80 = good agreement; 0.80–1.00 = very good agreement.)
f i g u r e  3  Rating of 80 cases with potential for clinical impact (radia-
tion oncologist 1 by radiation oncologist 2). Weighted kappa (95% 
confidence limits): 0.20 (–0.03, 0.44). (Kappa < 0.20 = poor agree-
ment; 0.20–0.40 = fair agreement; 0.40–0.60 =moderate agreement; 
0.60–0.80 = good agreement; 0.80–1.00 = very good agreement.)
t a b l e  iii  Clinical–pathologic characteristics of included cases 
derived from 93 original surgical pathology reports
Characteristic [n (%)]
Breast-conserving surgery 49 (53)
Modified radical mastectomy 44 (47)
Invasive carcinoma 81 (87)
In situ carcinoma 12 (13)
Hormone receptor status
Negative 5 (5)
Positivea 32 (34)
Not determined or not describedb 56 (60)
Nodal status
Not involved 49 (53)
Involved 28 (30)
Not determined or described 16 (17)
a  Includes estrogen receptor (e r) +/progesterone receptor (p r) +, 
e r+/p r–, and e r–/p r+.
b  Includes cases from hospitals that do not perform hormone re-
ceptor testing on site and cases in which hormone receptor test-
ing was performed on site, but is still pending at time of referral.29
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t a b l e  iv  Clinical features of cases with agreement on clinical impact within oncology specialitya
Case Age Surgery Pathology Main
discordant
elements
Potential
therapeutic
implications
Original Consultation
High clinical impact
1 61 Breast-conserving
surgery
Ductal carcinoma in situ Ductal carcinoma in situ
with microinvasion
Microinvasion Further surgery
2 66 Modified  
radical
mastectomy,
axillary lymph 
node dissection
Ductal carcinoma in situ, 1.5 cm
Nodes negative
Invasive ductal carcinoma
T1aN0
Grade 2
l v i -negative
Invasion Offer hormone 
therapy
3 55 Modified radical
mastectomy,
axillary lymph 
node dissection
Invasive ductal and invasive  
lobular carcinoma, 0.5 cm
T1aN0
Grade 2
l v i -negative
Invasive ductal and invasive lobular 
carcinoma, 1.3 cm
T1cN0
Grade 1
l v i -negative
e r+/p r+
Tumour stage Offer
systemic  
adjuvant
therapy
4 71 Modified radical
mastectomy,
axillary lymph 
node dissection
Invasive ductal carcinoma
T2N2
Grade 2
l v i -positive
e r +/p r+
Invasive ductal carcinoma
T2N2
Grade 3
l v i -positive
e r –/p r–
Hormone 
receptor status
Do not offer
hormone 
therapy
5 51 Breast-conserving
surgery sentinel 
lymph node
Invasive ductal carcinoma
T1aN1mi
(1/3 micrometastasis)
 
Grade 2
l v i -negative
Invasive ductal carcinoma
T1aN0(i+)
(2/3 nodes with isolated tumour 
cells)
Grade 2
l v i -negative
e r+/p r+
Nodal stage Do not offer 
chemotherapy; 
perform 
axillary lymsph 
node dissection
6 51 Breast-conserving
surgery, axillary 
lymph node
dissection
Invasive ductal carcinoma
T1cN0
Grade 1
l v i -negative
e r –/p r–
Invasive ductal carcinoma
T1cN0
Grade 1
l v i -negative
e r +/p r+
Hormone  
receptor  
status
Offer hormone 
therapy
Medium clinical impact
7 56 Modified radical
mastectomy,
axillary lymph 
node dissection
Invasive ductal carcinoma, 2.0 cm
T1cN0
Grade 3
l v i  not described
Invasive ductal carcinoma, 2.2 cm
T2N0
Grade 3
l v i  present
e r–/p r–
Tumour size
LVI status
More  
emphasis on 
chemotherapy
8 77 Breast-conserving
surgery, mam-
mary node
Invasive ductal carcinoma
T2N0
Margins negative (5 mm)
Grade 3
Cannot determine l v i
Invasive ductal carcinoma
T2N0
Margins negative (1 mm)
Grade 3
l v i  present
e r+/p r+
Change in 
distance
to nearest 
margin
Add
radiotherapy 
boost
9 43 Completion
mastectomy,
axillary lymph 
node dissection
Invasive ductal carcinoma, size not clear
N1
Ductal carcinoma in situ
6 mm from margin
Grade 3
l v i  absent
e r+/p r+
Invasive ductal carcinoma
T1cN1
Ductal carcinoma in situ
less than 1 mm from margin
Grade 3
l v i  present
e r+/p r–
Change in 
distance
to nearest 
margin
Add
radiotherapy 
boost
a  Boldface type emphasizes areas of discordance.
l v i  = lymphovascular invasion; e r = estrogen receptor; p r = progesterone receptor.30
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impact by both medical oncologists. These cases 
included a change from in situ to microinvasive or in-
vasive disease (2 cases), change in hormone receptor 
status (2 cases), change in nodal stage (1 case), and 
change in tumour size or T stage (1 case). The single 
discordant case rated as having medium clinical im-
pact by both medical oncologists included a change 
in both tumour size and lymphovascular invasion 
status. The 3 cases rated by both radiation oncologists 
as having medium clinical impact involved margin 
status. Table iv summarizes the potential therapeutic 
implications of discordant elements for the cases in 
which there was agreement between subspecialists 
regarding potential clinical impact.
4.  DISCUSSION
In the mid-1990s, the primarily U.S.-based Associa-
tion of Directors of Anatomic and Surgical Pathol-
ogy recommended that review of outside pathology 
should be standard policy before patient treatment 
at a different institution 10. In practice, however, 
inter-institutional pathology consultation is variably 
applied 11,12. Suggested reasons for variability in the 
adoption of routine second-opinion pathology include 
workload constraints 5, financial costs 6, uncertainty 
about the value of reviews, and concerns about 
treatment delay 4.
Our institution had a policy of routine review 
upon referral in all cases of breast cancer patients 
with original pathology reported at an outside institu-
tion. Although the literature contains many studies of 
inter-institutional pathology consultations, our study 
is one of the few to examine breast cancer–specific 
inter-institutional pathology consultations and to 
assess the impact of discordant reporting on clinical 
decision-making.
Among 93 randomly selected inter-institutional 
pathology consultations for breast cancer at our 
institution, 10 (11%) had discordance with clinical 
impact as demonstrated by agreement within specialty 
by medical and radiation oncologist reviewers. Our 
results are in a range similar to that for discordance 
rates observed in other studies of inter-institutional 
pathology consultations.
In four large studies of inter-institutional pathol-
ogy consultations in general pathology, rates of major 
discordance ranged from 1.4% to 9.0% 3–6. The lower 
value is from a study of 6171 cases referred to the 
Johns Hopkins Hospital, which mandates second 
opinion for surgical pathology from outside hospi-
tals 3. In that study, a changed diagnosis was defined 
as “a discordant diagnosis resulting in a major modi-
fication in therapy or prognosis.” Manion et al., using 
a similar definition of major discordance, observed 
a 2.3% major discordance rate and a 9.0% minor 
disagreement rate for 5629 cases in Iowa City 6. A 
review performed at the only cancer centre in Taiwan 
observed major discordance in 6% of mandatory inter-
institutional pathology consultations 5. Weir et al. at 
the University Health Network in Toronto observed 
a 6.8% discordance rate in 1000 randomly selected 
consultations 4. In both the Iowa City and Toronto 
studies, approximately half the discordant findings 
had clinical impact.
More recently, a study comparing pathology 
report discordance relating to patients with non-
Hodgkin lymphoma in the National Comprehensive 
Cancer Network was reported. The authors observed 
discordant reports in 43 of 731 cases for an overall 
rate of 6%. Of the discordant cases, 35 (81%) may 
have had treatment altered as a result of pathology 
reclassification 7.
In three of the four general pathology studies, 
discordance rates for breast cancer cases are reported 
or can be elucidated separately. Kronz et al. at Johns 
Hopkins found 1.4% of breast cases to be discordant 3, 
with most discordances involving differentiation 
between in situ and invasive disease, and 1 case in-
volving a change in nodal status. The Toronto group 
reported discordance in 4.1% of breast cases 4. In the 
Taiwanese series, 6.3% of breast cases were observed 
Case Age Surgery Pathology Main
discordant
elements
Potential
therapeutic
implications
Original Consultation
10 60 Breast-conserving
surgery, axillary 
lymph node  
dissection
Invasive ductal carcinoma
with lobular features
T1bN1
Ductal carcinoma in situ
less than 1 mm from margin
Grade 3
Invasive ductal and  
invasive lobular carcinoma
T1cN1
In situ and invasive carcinoma
2 mm from margin
Grade 3
l v i  absent
e r+/p r+
Change in 
distance
to nearest 
margin
Do not add
radiotherapy 
boost
a  Boldface type emphasizes areas of discordance.
l v i  = lymphovascular invasion; e r = estrogen receptor; p r = progesterone receptor.
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to be discordant, with most of those involving dif-
ferentiation between in situ and invasive disease, or 
between histologic tumour types 5. In our study, inter-
institutional pathology consultation revealed invasive 
components in 2 cases originally reported as ductal 
carcinoma in situ. Other reasons for case discordance 
with agreement on clinical impact included tumour 
size, hormone receptor status, nodal stage, margin 
status, and presence of lymphovascular invasion. No 
case in our study involved an incorrect diagnosis of 
a breast neoplasm.
Staradub et al. reported major changes in surgi-
cal therapy in 7.8% of cases resulting from second-
opinion pathology review after a biopsy diagnosis 
of invasive or in situ breast carcinoma 13. Most of 
those cases involved discordance between in situ and 
invasive disease or a change in margin status. In 80% 
of cases in that study, there were also differences in 
pathology or prognostic factors between the original 
and the review opinions.
In a study of 149 breast cancer cases undergoing 
multidisciplinary case review in Michigan, pathology 
interpretation changed in 43 (29%), and surgical plans 
were altered in 13 (9%) based on pathology review 
alone 9. A similar study of 77 patients revealed a ma-
jor discordance in 3 (4%) cases, all of which led to a 
change in therapy 8.
Our study differs from the investigations of 
changes in surgical management by our focus on the 
clinical effect of discordant pathology reports for 
recommendations regarding adjuvant systemic or ra-
diation therapy for breast cancer. As a result, elements 
included in our study—such as changes in tumour 
size, hormone receptor status, and lymphovascular 
invasion—were not specifically noted by the other 
studies. Interestingly, despite differences in meth-
odology and definitions of clinical impact, the rate 
of discordance with clinical impact in our study was 
consistent with rates observed in previous studies.
Our results have certain limitations. We designed 
our study to require clinicians to make an explicit 
statement about the impact of the pathology consulta-
tion in the context of each individual patient scenario. 
Providing a summary of the original and consultation 
reports, together with information about patient age 
and type of surgery, aimed to simulate the setting in 
which clinical decision-making occurs; however, this 
approach cannot be assumed to accurately reflect 
an actual clinical decision reached at the oncology 
consultation. Our methodology focused on individual 
oncologist assessment of clinical impact, which may 
be subject to considerable variability based on exper-
tise or clinical focus. Indeed, in 22 of 93 consulta-
tions, medical oncologists disagreed on independently 
performed ratings of clinical impact, and in 13 of 93, 
radiation oncologists disagreed.
The criteria for designation of clinical impact 
were specified and operationalized to maximize 
consistency. However, the clinical judgment of the 
individual reviewer may have resulted in differences 
in the interpretation of the relative clinical importance 
of the discordant reports. For example, one medical 
oncologist more often commented on additional sur-
gical management; the other focused predominantly 
on changes in systemic therapy.
The inclusion of “different emphasis on a treat-
ment modality” in the criteria for medium impact 
may also have increased variability. Some disagree-
ment is not unexpected and likely represents areas 
of clinical uncertainty and variation in practice pat-
terns. We did not allow for consensus discussion to 
resolve disagreements, as may occur during formal 
multidisciplinary tumour rounds. Our methodology 
may therefore overestimate the degree of clinical 
disagreement that might otherwise be mediated by 
consensus opinion, and it cannot be generalized to 
multidisciplinary tumour boards as exist in most 
major oncology centres, including our own.
Some discordant elements in our study were 
identified as a result of re-cutting of tissue blocks 
during the pathology consultation. The examination 
of additional sections is common during pathology 
consultations and may yield additional information 
even when adequate tissue sampling occurred during 
the initial gross specimen evaluation. Thus, in theory, 
the findings of the consultation report may reflect 
evaluation of additional slides rather than discordance 
in interpretation. We were unable to determine the 
extent to which additional sectioning occurred in 
our study because we collected data from pathology 
reports, but did not perform a retrospective pathology 
review as part of our protocol.
The second pathology opinion, often performed 
at a referral centre by an expert in the disease site of 
interest, is often assumed to be correct. However, 
in a small percentage of cases, studies that obtained 
clinical follow-up have observed that the original 
interpretation was indeed correct or that neither the 
initial nor the second opinion was correct 3,5,6. It has 
been suggested that the true “gold standard” in assess-
ment of the accuracy of a pathology report is the clini-
cal course of the disease 6, but that course is usually 
altered by therapeutic interventions and is difficult to 
directly relate to specific pathologic factors.
It was encouraging to note that our study identi-
fied no case originally diagnosed as malignant that 
was reviewed as benign, and no misdiagnosis of a 
non-carcinomatous breast neoplasm such as lym-
phoma, sarcoma, or secondary neoplasm metastatic 
to the breast. It remains possible, however, that neo-
plasms incorrectly diagnosed as benign could be 
underrepresented, because most cases with an origi-
nal diagnosis of benign breast disease would not be 
systematically referred to the QEII Health Sciences 
Centre and would not, therefore, have been included 
in our cohort of potentially eligible cases.
It was also reassuring to find only 2 discordant 
results involving hormone receptor status. Our study 
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found only one estrogen and progesterone receptor–
negative (e r–/p r–) tumour that was subsequently 
reported as e r+/p r+. In Nova Scotia, a few hospitals 
perform hormone receptor testing on site; the remain-
der of the testing is performed at the QEII Health 
Sciences Centre 14. To minimize the risk of false 
negatives, e r–/p r– tumours diagnosed at hospitals 
performing on-site testing are routinely reviewed 
upon patient referral to the QEII for adjuvant therapy 
recommendations.
The consultations in our study occurred in 2004, 
which was before province-wide synoptic reporting 
for breast cancer was implemented in Nova Scotia. 
Although missing information was not a major fac-
tor in the 10 discordant consultations consistently 
rated as having clinical impact, reports that would 
be incomplete according to current synoptic report-
ing guidelines were not infrequent (data not shown). 
Whether the adoption of synoptic reporting has 
affected discordance in breast cancer pathology re-
porting in Nova Scotia is not known at this time, but 
synoptic reporting should—at least theoretically—
result in fewer reports with missing information on 
key prognostic factors.
5.  CONCLUSIONS
Of 93 randomly selected inter-institutional pathology 
consultations for breast cancer, 10 (11%) were found 
to have discordance with either high or medium clini-
cal impact as determined by agreement on clinical 
impact ratings within specialty by medical and radia-
tion oncologist reviewers. Many consultations had 
discordant elements that either had no clinical impact 
or for which reviewers disagreed on potential impact. 
These results further inform our breast site team on 
the practice and merits of inter-institutional pathology 
consultation for breast cancer in Nova Scotia. They 
will provide a basis for further research and quality 
assurance initiatives and will help to guide human 
resource requirements in pathology. These results may 
also stimulate other investigators to examine similar 
questions within the Canadian context.
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